Literature DB >> 1323068

Lipoprotein(a) in patients with proteinuria.

M E Thomas1, A Freestone, Z Varghese, J W Persaud, J F Moorhead.   

Abstract

Lipoprotein(a) (Lp(a)) has recently been recognized to be a risk factor for coronary heart disease. Lp(a) median values in the absence of renal disease are around 10 mg/dl. Higher levels (greater than or equal to 30 mg/dl) correlate with the occurrence of coronary heart disease, particularly in the presence of elevated cholesterol. We have studied Lp(a) in 76 adults with proteinuria. Fifty had glomerular diseases and 26 non-glomerular diseases, with renal function varying from normal to advanced chronic renal failure. Lp(a) values were shifted to the right, with a median of 21.0 mg/dl, and 25% of patients had values of 30 mg/dl or more. Lp(a) did not correlate with cholesterol, age, lipoprotein subclasses, apoproteins A-I or B-100, albumin, creatinine, or creatinine clearance. Median Lp(a) values did not differ significantly comparing men versus women, or glomerular versus non-glomerular disease. Lp(a) may inhibit fibrinolysis, and is deposited in atherosclerotic lesions. Although the cause of these elevated Lp(a) levels is uncertain, we propose that they contribute to the increased risk of coronary heart disease in the nephrotic syndrome, and may play a role in progressive renal disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1323068     DOI: 10.1093/ndt/7.7.597

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  What is the role of lipoprotein abnormalities and platelet aggregation defects in cardiovascular disease in chronic dialysis patients?

Authors:  J Winkler; G Boner; D Gavish; J Fuchs; I Weinberger
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

Review 2.  ACE inhibitors and proteinuria.

Authors:  R T Gansevoort; D de Zeeuw; P E de Jong
Journal:  Pharm World Sci       Date:  1996-12

Review 3.  Nephrology, dialysis and transplantation.

Authors:  K Farrington; P Sweny
Journal:  Postgrad Med J       Date:  1993-07       Impact factor: 2.401

4.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

5.  Serum Lp(a) in diabetics with and without evidence of clinical nephropathy-A preliminary study.

Authors:  S Jaya Kumari; Nivedita Jayaram; Lloyd Vincent; T Venkatesh
Journal:  Indian J Clin Biochem       Date:  2002-01

Review 6.  Lipoprotein(a): new insights into an atherogenic lipoprotein.

Authors:  W Bartens; C Wanner
Journal:  Clin Investig       Date:  1994-08

Review 7.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.